Last update: June 11, 2018
Minimal risk for breastfeeding and infant.
First-generation antihistamine, piperazine derived drug with mild sedative effect. It is used as anxiolytic.
Oral or intramuscular administration up to 4 times a day.
It is metabolized into Cetirizine which is compatible with breastfeeding.
At last update no relevant information concerning breastfeeding were found.
Its pharmacokinetic characteristics (high plasma protein binding and large volume of distribution), make it very unlikely its excretion into breast milk in significant amounts.
Since it has been shown to be well tolerated by young infants for itching relief and because it is metabolized into Cetirizine, we would assume that there is a low risk for breastfeeding in short-term treatments.
Lethargy and adequate feeding of the infant should be monitored.
Co-sleeping with the baby is not recommended if this drug is being taken (UNICEF 2013, Landa 2012, ABM 2008, UNICEF 2006).
Its dopaminergic effect is anti-prolactin (dopamine inhibits prolactin secretion) and may decrease milk production during the first weeks after delivery. When breastfeeding is well established, prolactin levels are not correlated with milk production (Messinis 1985).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM